期刊文献+

98例迟发性呼吸机相关性肺炎患者的病原学及耐药性监测 被引量:2

Pathogenesis and drug resistance in 98 Patients with late-onset ventilator-associated pneumonia
下载PDF
导出
摘要 目的探讨迟发性呼吸机相关性肺炎(VAP)患者的病原菌分布和耐药性。方法将98例被确诊为迟发性VAP的机械通气患者进行病原学分布和耐药状况监测。结果纤维支气管镜采样98例共检出致病菌168株,革兰阴性菌占82.9%.其中非发酵菌占5012%,肠杆菌科占3217%;革兰阳性菌占1315%;真菌占4.6%。前3位致病菌分别为鲍氏不动杆菌(26.9%)、铜绿假单胞菌(13.6%)和肺炎克雷伯菌(10.5%)。药敏结果显示前几位革兰阴性菌对常用抗菌药物均有较高耐药性,草兰阳性茵均对万古霉素敏感。结论迟发性VAP的病原菌以革兰氏阴性茵为主,且呈现多重耐药现象,合适的经验性抗菌药物治疗应根据病原学与耐药性的监测结果。 Objective To probe the pathogenesis and their resistance to antibiotics of late-onset ventilator-associated pneumonia (VAP). Methods A clinical trial in late-onset VAP episodes of 98 patients receiving mechanical ventilation, The pathogenesis and their resistance to antibiotics were analyed. Results A total of 168 pathogen strains were isolated through fiberbronchoscopy by bacterial culture,The Gram-negative bacteria (GNB) were 82.9%, Non-fermenters were 51.4% and Enterobacteriaceae were 32.7% among it ,The Gram-positive bacteria were 13.5%,the fungi 4.6%.The top three pathogen strains with VAP were Acinetobacter baumanii(26.9%),Pseudomonas aeruginosa(13.6%),Klebsiella pneumoniae(10.5%) .GNB were highly resistant to common antimicrobials and demonstrated multi-drug resistance, Drug resistance of the Gram-positive bacteria to vancomycin was Conclusion The major pathogenic bacteria in late-onset VAP is GNB, and there are often demonstrated multi-drug resistance,It is suggested that empiric antimicrobial therapy for patients with late-onset VAP should base on the surveillance of etiology and resistance.
出处 《浙江医学》 CAS 2011年第8期1165-1167,共3页 Zhejiang Medical Journal
关键词 呼吸机相关性肺炎 抗生素 耐药性 纤维支气管镜 病原学 Ventilator-associated pneumonia Antibiotics Drug resistance Branchofiberoscope Etiology
  • 相关文献

参考文献5

二级参考文献41

  • 1冉陆,张静.全球食源性疾病监测及监测网络[J].中国食品卫生杂志,2005,17(4). 被引量:31
  • 2[1]Kollef MH. Antimicrobial therapy of ventilator-associate pneumonia. How to select an appropriate drug regimen. [J]. Chest,1999, 115(1):8
  • 3[2]Wunderink RG. Therapy for nesocomial pneumonia. [ J ]. Curr Opin Pulm Med, 1997,3(2): 120
  • 4[3]Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associafed pneumona. [J]. Chest, 1997,111: 676
  • 5[4]Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes:implications for the antibiotic management of ventilator-associated pneumonia. [J]. Chest, 1998,113:412
  • 6[5]Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. [J]. Am J Respir Crit Car Med, 1997,156:196
  • 7[6]Visnegarwala F, Lyer NG, Hamill RT. Ventilator-associated Pneumonia.[J].Inter J Antimicrob Agents,1998.10:191
  • 8[7]George DL, Falk PSH RG. Epidemiology of ventilator-acquired pneumonia based onprotected bronchoscopic sampling. [J]. Am J Respir Crit Care Med 1998. 158:1839
  • 9[8]Heyland DK. Cook DJ, Marshall J, et al. The clinical utility of invasive diagnosic techniques in the setting of ventilator-rassociated pneumonia. [J]. Chest, 1999,115: 1076
  • 10[9]Heyland DK, Cood DJ, Griffith L, et al. The atributabe morbidity and mortality of ventilator-associated pneumonia in the critically ill patent. [J]. Am J Respir Crit Care Med,1999,159:1249

共引文献334

同被引文献11

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部